Q Sue Huang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4274228/publications.pdf

Version: 2024-02-01

185998 114278 5,520 63 28 63 h-index citations g-index papers 69 69 69 8911 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet, The, 2018, 391, 1285-1300.	6.3	1,870
2	Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infectious Diseases, The, 2012, 12, 687-695.	4.6	1,047
3	Impact of the COVID-19 nonpharmaceutical interventions on influenza and other respiratory viral infections in New Zealand. Nature Communications, 2021, 12, 1001.	5.8	268
4	Evaluation of rapid and simple techniques for the enrichment of viruses prior to metagenomic virus discovery. Journal of Virological Methods, 2014, 195, 194-204.	1.0	181
5	The contrasting phylodynamics of human influenza B viruses. ELife, 2015, 4, e05055.	2.8	166
6	Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study. Influenza and Other Respiratory Viruses, 2015, 9, 3-12.	1.5	150
7	The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS ONE, 2019, 14, e0222381.	1.1	102
8	Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis. PLoS Medicine, 2021, 18, e1003550.	3.9	101
9	Genomic epidemiology reveals transmission patterns and dynamics of SARS-CoV-2 in Aotearoa New Zealand. Nature Communications, 2020, 11, 6351.	5.8	100
10	Influenza vaccine effectiveness in preventing influenza-associated intensive care admissions and attenuating severe disease among adults in New Zealand 2012–2015. Vaccine, 2018, 36, 5916-5925.	1.7	91
11	Risk Factors and Immunity in a Nationally Representative Population following the 2009 Influenza A(H1N1) Pandemic. PLoS ONE, 2010, 5, e13211.	1.1	90
12	Sexual Transmission of Zika Virus and Persistence in Semen, New Zealand, 2016. Emerging Infectious Diseases, 2016, 22, 1855-1857.	2.0	75
13	Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New Zealand. Lancet, The, 2005, 366, 394-396.	6. 3	70
14	A chest radiograph scoring system in patients with severe acute respiratory infection: a validation study. BMC Medical Imaging, 2015, 15, 61.	1.4	65
15	Temporal Patterns of Influenza A and B in Tropical and Temperate Countries: What Are the Lessons for Influenza Vaccination?. PLoS ONE, 2016, 11, e0152310.	1.1	58
16	Genomic Evidence of In-Flight Transmission of SARS-CoV-2 Despite Predeparture Testing. Emerging Infectious Diseases, 2021, 27, 687-693.	2.0	58
17	Seasonal influenza vaccine policies, recommendations and use in the World Health Organization's Western Pacific Region. Western Pacific Surveillance and Response Journal: WPSAR, 2013, 4, 51-59.	0.3	52
18	Literature review of the epidemiology of influenza B disease in 15 countries in the Asiaâ€Pacific region. Influenza and Other Respiratory Viruses, 2018, 12, 383-411.	1.5	50

#	Article	IF	CITATIONS
19	Severe Influenza Is Characterized by Prolonged Immune Activation: Results From the SHIVERS Cohort Study. Journal of Infectious Diseases, 2018, 217, 245-256.	1.9	44
20	Risk of Severe Influenza Among Adults With Chronic Medical Conditions. Journal of Infectious Diseases, 2020, 221, 183-190.	1.9	44
21	Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. Influenza and Other Respiratory Viruses, 2021, 15, 732-741.	1.5	44
22	Risk Factors and Attack Rates of Seasonal Influenza Infection: Results of the Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) Seroepidemiologic Cohort Study. Journal of Infectious Diseases, 2019, 219, 347-357.	1.9	43
23	Environmental Poliovirus Surveillance during Oral Poliovirus Vaccine and Inactivated Poliovirus Vaccine Use in Colrdoba Province, Argentina. Applied and Environmental Microbiology, 2009, 75, 1395-1401.	1.4	38
24	Influenza in the Asia-Pacific region: Findings and recommendations from the Global Influenza Initiative. Vaccine, 2017, 35, 856-864.	1.7	38
25	Distinct patterns of evolution between respiratory syncytial virus subgroups A and B From New Zealand isolates collected over thirty-seven years. Journal of Medical Virology, 2006, 78, 1354-1364.	2.5	37
26	Implementing hospital-based surveillance for severe acute respiratory infections caused by influenza and other respiratory pathogens in New Zealand. Western Pacific Surveillance and Response Journal: WPSAR, 2014, 5, 23-30.	0.3	36
27	Respiratory Syncytial Virus–Associated Hospitalizations Among Adults With Chronic Medical Conditions. Clinical Infectious Diseases, 2021, 73, e158-e163.	2.9	34
28	Pandemic (H1N1) 2009 and Seasonal Influenza A (H1N1) Co-infection, New Zealand, 2009. Emerging Infectious Diseases, 2010, 16, 1618-1620.	2.0	32
29	Influenza-Associated Outcomes Among Pregnant, Postpartum, and Nonpregnant Women of Reproductive Age. Journal of Infectious Diseases, 2019, 219, 1893-1903.	1.9	31
30	Epidemiologic and virologic assessment of the 2009 influenza A (H1N1) pandemic on selected temperate countries in the Southern Hemisphere: Argentina, Australia, Chile, New Zealand and South Africa. Influenza and Other Respiratory Viruses, 2011, 5, e487-e498.	1.5	29
31	An Echovirus Type 33 Winter Outbreak in New Zealand. Clinical Infectious Diseases, 2003, 37, 650-657.	2.9	28
32	Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance. Influenza and Other Respiratory Viruses, 2015, 9, 179-190.	1.5	28
33	Use of Genomics to Track Coronavirus Disease Outbreaks, New Zealand. Emerging Infectious Diseases, 2021, 27, 1317-1322.	2.0	28
34	The effectiveness of seasonal trivalent inactivated influenza vaccine in preventing laboratory confirmed influenza hospitalisations in Auckland, New Zealand in 2012. Vaccine, 2014, 32, 3687-3693.	1.7	27
35	Acute Flaccid Paralysis from Echovirus Type 33 Infection. Journal of Clinical Microbiology, 2003, 41, 2230-2232.	1.8	26
36	Influenza vaccine effectiveness for hospital and community patients using control groups with and without non-influenza respiratory viruses detected, Auckland, New Zealand 2014. Vaccine, 2016, 34, 503-509.	1.7	25

#	Article	IF	Citations
37	A Modular Cytokine Analysis Method Reveals Novel Associations With Clinical Phenotypes and Identifies Sets of Co-signaling Cytokines Across Influenza Natural Infection Cohorts and Healthy Controls. Frontiers in Immunology, 2019, 10, 1338.	2.2	25
38	Influenza surveillance and immunisation in New Zealand, 1997–2006. Influenza and Other Respiratory Viruses, 2008, 2, 139-145.	1.5	22
39	Rotavirus hospitalisation in New Zealand children under 3 years of age. Journal of Paediatrics and Child Health, 2006, 42, 196-203.	0.4	21
40	Self-diagnosis of influenza during a pandemic: a cross-sectional survey. BMJ Open, 2011, 1, e000234-e000234.	0.8	20
41	Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases. Nature Communications, 2021, 12, 4313.	5.8	17
42	Heterogeneity in influenza seasonality and vaccine effectiveness in Australia, Chile, New Zealand and South Africa: early estimates of the 2019 influenza season. Eurosurveillance, 2019, 24, .	3.9	17
43	Genomic epidemiology of Delta SARS-CoV-2 during transition from elimination to suppression in Aotearoa New Zealand. Nature Communications, 2022, 13, .	5.8	17
44	Respiratory syncytial virus hospitalisations among young children: a data linkage study. Epidemiology and Infection, 2019, 147, e246.	1.0	16
45	The health and economic burden of respiratory syncytial virus associated hospitalizations in adults. PLoS ONE, 2020, 15, e0234235.	1.1	16
46	Influenza surveillance in New Zealand in 2005. New Zealand Medical Journal, 2007, 120, U2581.	0.5	15
47	Modelled seasonal influenza mortality shows marked differences in risk by age, sex, ethnicity and socioeconomic position in New Zealand. Journal of Infection, 2017, 75, 225-233.	1.7	14
48	Estimating the contribution of influenza to hospitalisations in New Zealand from 1994 to 2008. Vaccine, 2015, 33, 4087-4092.	1.7	11
49	Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling. Journal of Antimicrobial Chemotherapy, 2012, 67, 2949-2956.	1.3	10
50	Surveillance for Influenza Using Hospital Discharge Data May Underestimate the Burden of Influenza-Related Hospitalization. Infection Control and Hospital Epidemiology, 2012, 33, 1064-1066.	1.0	10
51	Temporal Variations in Respiratory Syncytial Virus Epidemics, by Virus Subtype, 4 Countries. Emerging Infectious Diseases, 2021, 27, 1537-1540.	2.0	9
52	Seroepidemiologic Effects of Influenza A(H1N1)pdm09 in Australia, New Zealand, and Singapore. Emerging Infectious Diseases, 2013, 19, 92-101.	2.0	8
53	Interactive effects of age and respiratory virus on severe lower respiratory infection. Epidemiology and Infection, 2018, 146, 1861-1869.	1.0	7
54	Sensitivity and specificity of surveillance case definitions in detection of influenza and respiratory syncytial virus among hospitalized patients, New Zealand, 2012–2016. Journal of Infection, 2022, 84, 216-226.	1.7	7

#	Article	lF	Citations
55	Respiratory Virus-related Emergency Department Visits and Hospitalizations Among Infants in New Zealand. Pediatric Infectious Disease Journal, 2020, 39, e176-e182.	1.1	5
56	Identification of Enterovirus C105 for the first time in New Zealand. Western Pacific Surveillance and Response Journal: WPSAR, 2015, 6, 60-2.	0.3	5
57	Comparison of the pandemic H1N1 2009 experience in the Southern Hemisphere with pandemic expectations. Australian and New Zealand Journal of Public Health, 2012, 36, 364-368.	0.8	4
58	Activated CD4+ TÂcells and CD14hiCD16+ monocytes correlate with antibody response following influenza virus infection in humans. Cell Reports Medicine, 2021, 2, 100237.	3.3	4
59	Modelling the impact of respiratory syncytial virus (RSV) vaccine and immunoprophylaxis strategies in New Zealand. Vaccine, 2021, 39, 4383-4390.	1.7	3
60	Enterovirus 74 Infection in Children. PLoS ONE, 2013, 8, e76492.	1.1	2
61	Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection. Journal of Virology, 2020, 94, .	1.5	2
62	Tracking oseltamivir-resistance in New Zealand influenza viruses during a medicine reclassification in 2007, a resistant-virus importation in 2008 and the 2009 pandemic. Western Pacific Surveillance and Response Journal: WPSAR, 2012, 3, 79-85.	0.3	1
63	Pandemic Seasonal H1N1 Reassortants Recovered from Patient Material Display a Phenotype Similar to That of the Seasonal Parent. Journal of Virology, 2016, 90, 7647-7656.	1.5	0